Clinical Trial: A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions

U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07645209) titled 'A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions' on June 08.

Brief Summary: Hepatocellular carcinoma (HCC) is a common global malignancy. In China, the disease burden is substantial: HCC ranks fifth in cancer incidence and third in mortality, with a 5-year relative survival of only 14.4%. In Northeast China's cold regions, metabolic diseases such as hypertension, hyperlipidemia, and diabetes are prevalent and may influence HCC prognosis. Recently, PD-1/PD-L1 inhibitor-based combination regimens (with targeted therapy, chemotherapy, or locoregional treatment) have achieved major brea...